Bonus BioGroup
Press Room

Tuesday, 11 December 2018 07:01

Bonus BioGroup Announces Chief Scientist Support of Joint Research with Technion Totaling 1.4 Million NIS

Rate this item
(0 votes)

Bonus BioGroup Announces Chief Scientist Support of Joint Research with Technion Totaling 1.4 Million NIS


logo4footer

Bonus BioGroup announces today (Tuesday) approval by the Israeli Chief Scientist of a 1.4 million NIS joint program with the Technion. The research may enhance the attachment of mesenchymal and stem cells to the personalized pre-designed scaffold onto which they are seeded during transplant manufacture.

The research will take place at the Company’s R&D center at MATAM Advanced Technology Park in Haifa and at the National Institute of Stem Cell Technologies headed by Prof. Joseph Itskovitz-Eldor – Director of the Department of Obstetrics and Gynecology at Rambam Health Care Campus and full professor at the Faculty of Medicine of the Technion. Prof. Itskovitz-Eldor will lead the Technion’s scientific team who will carry out the joint project together with the Company’s researchers.

Prof. Itskovitz-Eldor is known for initiating the collaboration with James Thomson of the University of Wisconsin which has brought about the first production of human embryonic stem cells in the world, which is considered one of the most important scientific breakthroughs in medical history, alongside the human genome project DNA cloning. Prof. Itskovitz-Eldor derived the first human embryonic stem cells in Israel and these were approved for federal funding by the US and Germany.  

Dr. Shai Meretzki, CEO of Bonus BioGroup commented, “We are pleased to receive this support for the development of our Company’s unique technologies. This is the second award Bonus receives from the Chief Scientist, and this underlines the high value and confidence shown towards the Company’s continual technological development. Establishing collaborations with acclaimed leaders is a company strategy and indeed Prof. Itskovitz-Eldor is a pioneer and a world leader in the fields of stem cell and tissue engineering research. We believe his contribution towards further development of our pipeline will be significant.”     

Support provided by the Office of the Chief Scientist will amount to 910 thousand NIS out of the total approved budget for this research of 1.4 million NIS. Bonus BioGroup’s share will be in the amount of 516 thousand NIS.  

The Company announced several weeks ago that it had started establishing a first-of-its-kind human bone graft manufacturing facility in the Company’s 750sqm complex at MATAM Advanced Technology Park in Haifa. The facility will consist of three divisions: a manufacturing facility for producing human bone grafts to be utilized within the company's clinical trials planned to commence within several months, an R&D center, committed to ongoing pursuit of performance excellence and exploration of additional applications of the Company's human bone grafts, and headquarters for Bonus BioGroup's management, from which it will also supervise its projected R&D activities in the United States.

Read 1540 times Last modified on Tuesday, 11 December 2018 08:50

FOR MORE INVESTOR RELATION INFORMATION

Press Release, Announcements publication and more

Bonus BioGroup

Image

 

Terms of UsePrivacy Policy | Login        

© 2021 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.